biotechnology « Science and Enterprise

HHS Directs $100M for Covid-19 Venture Investments

By Alan, on August 23rd, 2023%

The Department of Health and Human Services is allocating $100 million for venture investments in new technologies to prepare for future threats from Covid-19. . . . → Read More: HHS Directs $100M for Covid-19 Venture Investments

Company Gains Ultrasound-Linked Drug Capsule Technology

By Alan, on August 21st, 2023%

A company developing a drug delivery process with treatments activated by ultrasound received an option to license a key technology from its founders’ university labs. . . . → Read More: Company Gains Ultrasound-Linked Drug Capsule Technology

Biotech, A.I. Companies Model Animal Studies/Clinical Trials

By Alan, on August 18th, 2023%

A discoverer of neuroscience therapies and a genomics data science company are developing machine learning models to predict clinical trial outcomes for ADHD drugs. . . . → Read More: Biotech, A.I. Companies Model Animal Studies/Clinical Trials

Trial Underway Testing Stem Cell Particles for Burns

By Alan, on August 16th, 2023%

A clinical trial has begun testing an experimental treatment for burns using off-the-shelf therapeutic particles derived from human bone marrow stem cells. . . . → Read More: Trial Underway Testing Stem Cell Particles for Burns

Regeneron Acquires Hearing Loss Biotech in $213M Deal

By Alan, on August 9th, 2023%

Regeneron Pharmaceuticals, a maker of synthetic biologic treatments, is acquiring Decibel Therapeutics, developer of gene therapies to treat hearing loss and balance disorders. . . . → Read More: Regeneron Acquires Hearing Loss Biotech in $213M Deal

Companies to Assess Ovarian Health Biotech Drug

By Alan, on August 8th, 2023%

A women’s health biotechnology company is partnering with a Brazilian drug maker to evaluate a precision target and treatment for ovarian health disorders. . . . → Read More: Companies to Assess Ovarian Health Biotech Drug

Trial Shows Vaccine Induces Chikungunya Immune Response

By Alan, on August 7th, 2023%

Initial findings from a large clinical trial testing a vaccine against the chikungunya virus show the vaccine generates protective antibodies in the vast majority of recipients. . . . → Read More: Trial Shows Vaccine Induces Chikungunya Immune Response

Trial Advances of Dual-Action Cancer Immunotherapy

By Alan, on August 3rd, 2023%

A clinical trial assessing a synthetic antibody to generate an immediate response and also generate a more durable treatment for solid tumor cancers, advanced to a mid-stage study. . . . → Read More: Trial Advances of Dual-Action Cancer Immunotherapy

Digital Chemistry Start-Up Gains $43M in Early Funds

By Alan, on August 2nd, 2023%

A company, spun-off from academic labs that designs and produces new chemicals with artificial intelligence and robotics, is raising $42.7 million in its first venture funding round. . . . → Read More: Digital Chemistry Start-Up Gains $43M in Early Funds

Companies Partner on Fast Production of Biologics in Plants

By Alan, on August 1st, 2023%

The developer of a biologic drug-making process with engineered plant crops is collaborating with a vertical farming company to create a network of biologics production facilities. . . . → Read More: Companies Partner on Fast Production of Biologics in Plants

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise